Earnings
Dianthus Now Sees Its CIDP Trial Needing Fewer Than 200 Open-Label Patients, With $1.2 Billion Of Cash Lasting Into 2030
The biotech reported a $46.6 million third-quarter net loss and set Part A results for year-end 2027 and a multifocal motor neuropathy readout for December.